Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

TD Cowen had upgraded Merck in early 2024 based on confidence in Keytruda and Gardasil’s performance, a lack of binary risks, and an attractive valuation. However, setbacks in Gardasil’s China sales ...

They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

Shares of Merck & Co. Inc. fell more than 0.5% on Monday afternoon, tracking their fifth consecutive decline in the worst ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

In a grim update, Merck announced it is temporarily halting shipments of HPV vaccine Gardasil—its second-biggest product—to China. “Like many other companies, we’ve seen increased pressure ...

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

In this piece, we will look at the stocks Jim Cramer recently discussed.